GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (WBO:PHM) » Definitions » Retained Earnings

Pharma Mar (WBO:PHM) Retained Earnings : €168.4 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Pharma Mar Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Pharma Mar's retained earnings for the quarter that ended in Dec. 2024 was €168.4 Mil.

Pharma Mar's quarterly retained earnings increased from Jun. 2024 (€144.4 Mil) to Sep. 2024 (€148.4 Mil) and increased from Sep. 2024 (€148.4 Mil) to Dec. 2024 (€168.4 Mil).

Pharma Mar's annual retained earnings declined from Dec. 2022 (€156.5 Mil) to Dec. 2023 (€142.2 Mil) but then increased from Dec. 2023 (€142.2 Mil) to Dec. 2024 (€168.4 Mil).


Pharma Mar Retained Earnings Historical Data

The historical data trend for Pharma Mar's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Retained Earnings Chart

Pharma Mar Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.87 121.29 156.51 142.22 168.38

Pharma Mar Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.22 144.09 144.43 148.42 168.38

Pharma Mar Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Pharma Mar  (WBO:PHM) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Pharma Mar Business Description

Address
Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.